Skip to main content

Month: March 2023

Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP – – Presented interim data from natural history study, ILLUMINATE, at Company-hosted ALSP KOL event in December 2022 – – Appointed David Gray, Ph.D., as Chief Science Officer – WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent progress. “In 2022, we made considerable progress in advancing VGL101 and our small molecule TREM2 agonist program through significant clinical and preclinical milestones, respectively. We shared important data...

Continue reading

Bitfarms Reports Fourth Quarter and Full Year 2022 Results

– Mined 1,434 BTC in Q4 2022; 5,167 BTC in 2022;and 20,000+ BTC since inception through February 2023 –– Averaged direct cost of production of $10,000 per BTC in 2022-– Reported Q4 2022 net loss of $17 million and positive Adjusted EBITDA of $1 million –– Expects over 30% increase in hashrate to 6.0 EH/s with existing portfolio by year-end 2023 – This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated August 16, 2021 to its short form base shelf prospectus dated August 12, 2021. TORONTO, Ontario and BROSSARD, Québec, March 21, 2023 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ: BITF // TSX: BITF), a global Bitcoin vertically integrated company, reported its financial results for the fourth quarter and year ended December 31, 2022....

Continue reading

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

LONDON, March 21, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022.Full year 2022 revenues of $254.5 million. Q4 2022 revenue of $41.1 million compared to Q3 2022 revenue of $42.2 million; strong position in a changing COVID testing market. Increased our installed base by more than 1,500 Platform instruments, primarily in Europe, driven by new product sales in diabetes, inflammation, heart failure and respiratory disease. Demonstrating Platform consolidation strategy in UK and Germany.         Commenced commercial shipments of heart failure tests in Europe. Working with the Independent Test Assessment Program (ITAP) established by the National Institutes of Health (NIH)...

Continue reading

Ducommun Incorporated Enters into Definitive Agreement to Acquire BLR Aerospace

Leading Provider of Proprietary Aerodynamic Systems that Enhance the Productivity, Performance and Safety of Rotary- and Fixed-Wing Aircraft SANTA ANA, Calif., March 21, 2023 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE:DCO) (“Ducommun” or the “Company”) today announced that it entered into a definitive securities purchase agreement (the “Transaction”) to acquire BLR Aerospace, LLC (“BLR”) on March 20,2023. The Transaction is subject to customary closing conditions and regulatory approval, and is expected to be completed during the second quarter of 2023. “I am delighted to welcome the team at BLR Aerospace to Ducommun as we continue to add proprietary engineered products to our portfolio,” said Stephen G. Oswald, chairman, president and chief executive officer of Ducommun Incorporated. “This is a first step in our commitment...

Continue reading

Crawford United Corporation Announces Fourth Quarter and Full Year 2022 Results

Sales of $32.7 million for the quarter, an increase of 19.5% Sales of $127.8 million for the year, an increase of 22.6% Net Income of $6.6 million for the year and earnings per share of $1.89 EBITDA of $4.1 million for the quarter, an increase of 150.6% EBITDA of $13.7 million for the year, an increase of 27.1%CLEVELAND, March 21, 2023 (GLOBE NEWSWIRE) — Crawford United Corporation (OTC: CRAWA), a growth-oriented holding company serving diverse markets, today reported results for the three-month and twelve-month periods ended December 31, 2022. For the quarter ended December 31, 2022, sales were $32.7 million compared with $27.3 million in the same period last year, an increase of 19.5%.  In this quarter, the Company recorded operating income of $2.7 million compared with operating income of $0.7 million in the same period last...

Continue reading

DSV, 1023 – SHARE BUYBACK IN DSV A/S

Company Announcement No. 1023On 2 February 2023, we initiated a share buyback programme, as described in Company Announcement No. 1013. According to the programme, the company will in the period from 2 February 2023 until 26 April 2023 purchase own shares up to a maximum value of DKK 2,500 million, and no more than 4,000,000 shares, corresponding to 1.83% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day Number of shares bought back   Average transaction price   Amount DKK             Accumulated trading...

Continue reading

Form 8.3 – [DEVRO PLC 20 03 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree DEVRO PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early 2H 2023, and potential U.S. launch in 1H 2024 Announcement of data from ongoing chronic neutropenia Phase 2 trial and clarity on regulatory path forward planned in 2Q or 3Q 2023 Conference call to be hosted today at 9:00 a.m. ET BOSTON, March 21, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted key 2022 events and expected upcoming milestones. “We could not be more pleased with the progress we made in 2022...

Continue reading

AppTech Payments Corp. Announces 2023 Annual Shareholder Meeting

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech”) (NASDAQ: APCX) a Fintech company powering seamless, commerce between businesses and consumers, announced today it filed its proxy statement and will hold its Annual Shareholder Meeting on May 2, 2023, at 10:00 AM PST. To enable shareholders to attend regardless of their location, AppTech will hold the meeting virtually. Meeting details and instructions to access proxy materials have been disseminated to shareholders of record via direct mail in accordance with the notice and access model. Shareholders of record as of the March 8, 2023, are entitled to the notice of the Annual Meeting or any adjournment thereof. If you are a shareholder and have not received notice by April 7, 2023, please contact AppTech Investment Relations to obtain meeting...

Continue reading

Ruby Graphite Permit Applications Submitted to Bureau of Land Management

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) — Reflex Advanced Materials Corp. (CSE: RFLX), (OTCQB:RFLXF), (FSE:HF2) (“Reflex” or the “Company”) announces that, through agreement with the mineral rights owner, it has submitted permit applications to the Bureau of Land Management (BLM) in respect of its exploration of the Ruby Graphite project in Dillon, Montana. The Ruby Graphite project (the “Project”) covers approximately 2000 acres and 96 federal lode mining claims located in Beaverhead County, Montana, USA. The Company secured an option to acquire 100% ownership in the Project in September (see news release dated October 12, 2022). The Project is prospective for natural crystalline graphite due to its history of commercial graphite production. There is currently no commercial production of graphite in the United...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.